News|Articles|April 7, 2026

Q1 2026 Recap: Allergy News and Updates

Fact checked by: Tim Smith

FDA approvals, new HAE guidance, epinephrine access shifts, and phase 3 peanut patch data defined major allergy developments across Q1 2026.

The first quarter of 2026 delivered a series of regulatory milestones, guideline updates, and late-phase clinical data that reshaped key areas across allergy and immunology. US Food & Drug Administration (FDA) approvals expanded treatment options for pediatric hereditary angioedema (HAE) and allergic fungal rhinosinusitis. Label changes also expanded treatment options for anaphylaxis in children under 4 years old.